Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Obatoclax Mesylate (GX15-070) Chemical Structure

Obatoclax Mesylate (GX15-070) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

Customer Product Validation(9)

Quality Control & MSDS

Related Compound Libraries

Obatoclax Mesylate (GX15-070) is available in the following compound libraries:

Bcl-2 Inhibitors with Unique Features

  • Pan Bcl-2 Inhibitor

    ABT-737 Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

  • Most Potent Bcl-2 Inhibitor

    ABT-263 (Navitoclax) Bcl-xL, Ki≤ 0.5 nM; Bcl-2, Ki≤ 1 nM; Bcl-w, Ki≤ 1 nM.

  • Newest Bcl-2 Family Activator

    BAM7 Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Product Information

  • Compare Bcl-2 Inhibitors
    Compare Bcl-2 Products
  • Research Area

Product Description

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Targets Bcl-2 [1]
(Cell-free assay)
IC50 0.22 μM(Ki)
In vitro Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KARPAS-45M{fD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrDTWM2OD1yLkCwNFA{OTdizszNNYLLdIJWW0GQR1XS
SK-MEL-30MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlv2TWM2OD1yLkCwNFM2PSEQvF2=M1jMWXNCVkeHUh?=
NALM-6NFvX[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfzXIRKSzVyPUCuNFAxOzV4IN88US=>M{TI[3NCVkeHUh?=
KYSE-450M1jVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTBwMECwOFY6KM7:TR?=MnLvV2FPT0WU
BHYNX:xO2NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnzd|UzUUN3ME2wMlAxODZyMTFOwG0>NVvFSVRtW0GQR1XS
GR-STNX\QWG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTBwMECwOlQ5KM7:TR?=NWHWdGNCW0GQR1XS
786-0NUToeGg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTQZWxqUUN3ME2wMlAxODd5NjFOwG0>NGDuT5dUSU6JRWK=
C-33-AM3ixemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLmTWM2OD1yLkCwNFg1QCEQvF2=MkjLV2FPT0WU
BHT-101M1y5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrsTWM2OD1yLkCwNVA3KM7:TR?=NXrLNJQ{W0GQR1XS
EB2M4H1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDCZo9KSzVyPUCuNFAyOThizszNMlTiV2FPT0WU
G-361MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4ftWmlEPTB;MD6wNFEzPCEQvF2=MXzTRW5ITVJ?
KE-37M2XXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TmOWlEPTB;MD6wNFEzQCEQvF2=MXHTRW5ITVJ?
MHH-PREB-1NEjHV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DRe2lEPTB;MD6wNFE1KM7:TR?=NGnwdmpUSU6JRWK=
MCF7MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NED1fXpKSzVyPUCuNFAyPTlizszNNXHqSFhRW0GQR1XS
LOUCYMkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\pZ5h{UUN3ME2wMlAxOTd3IN88US=>MlrrV2FPT0WU
EW-7NIDBUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknwTWM2OD1yLkCwNVc2KM7:TR?=NH\uZ2VUSU6JRWK=
KYSE-510MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;HRoluUUN3ME2wMlAxOjN|IN88US=>NXfGNI96W0GQR1XS
SK-MEL-3M3fveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHGUFVKSzVyPUCuNFAzPjRizszNMn\lV2FPT0WU
HAL-01MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTBwMECyPVch|ryPNYfGSmt{W0GQR1XS
HCC2998MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTp[nRsUUN3ME2wMlAxOzN3IN88US=>M{ThdnNCVkeHUh?=
A375MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{jxO2lEPTB;MD6wNFM2KM7:TR?=NXK5dYRbW0GQR1XS
MZ7-melMnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XocWlEPTB;MD6wNFM6QSEQvF2=NGnvXmtUSU6JRWK=
SH-4NFu5NIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDDVnpqUUN3ME2wMlAxPDF5IN88US=>NFzWOI5USU6JRWK=
HT-144M3XR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1G4emlEPTB;MD6wNFQ{KM7:TR?=M2LI[3NCVkeHUh?=
KYSE-140M13Bfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjoO4RSUUN3ME2wMlAxPDN3IN88US=>Mom2V2FPT0WU
PSN1M4CwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTBwMEC0Olch|ryPNFziV4xUSU6JRWK=
COLO-679NEmxUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTBwMEC0PVgh|ryPNYqxTW9ZW0GQR1XS
SW620NXLkWJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfafHZCUUN3ME2wMlAxPTFzIN88US=>MkS2V2FPT0WU
HGC-27MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU[1cXBWUUN3ME2wMlAxPTJ2IN88US=>M1nqN3NCVkeHUh?=
IGROV-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTBwMEC2JO69VQ>?NYDDVoNDW0GQR1XS
IGR-1NFzERnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFG4VnVKSzVyPUCuNFA3ODFizszNMkDNV2FPT0WU
EW-1M4naWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlv1TWM2OD1yLkCwOlUyKM7:TR?=M3L3U3NCVkeHUh?=
769-PNFPKb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXnTWM2OD1yLkCwOlc5KM7:TR?=NIDqSIhUSU6JRWK=
HNNFj0fnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;D[|c1UUN3ME2wMlAxPjd7IN88US=>MoX5V2FPT0WU
SIG-M5NXLTdYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTBwMEC3NUDPxE1?NUnlTFdRW0GQR1XS
IST-MEL1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fNZmlEPTB;MD6wNFgyQCEQvF2=NWf0[25iW0GQR1XS
ST486NVnwN|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\h[GlEPTB;MD6wNFgzPSEQvF2=NYTFNFh7W0GQR1XS
ES7NXnTSoh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUL0OINMUUN3ME2wMlAxQDR4IN88US=>MVzTRW5ITVJ?
GAKMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXy1dIx1UUN3ME2wMlAxQDR6IN88US=>M1i0WXNCVkeHUh?=
BB30-HNCMoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nKfWlEPTB;MD6wNFg2QCEQvF2=NXLPUngzW0GQR1XS
IPC-298M1XjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwMEC5Nlch|ryPNFGwclFUSU6JRWK=
NKM-1NFvYS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVz6XIpSUUN3ME2wMlAxQTd{IN88US=>MlvEV2FPT0WU
RKOMmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorvTWM2OD1yLkCxNFQ1KM7:TR?=MVHTRW5ITVJ?
ACNNIrvTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlH3TWM2OD1yLkCxNVMyKM7:TR?=NEPwe2ZUSU6JRWK=
SW1417NGfWfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkexTWM2OD1yLkCxNlI2KM7:TR?=MlrQV2FPT0WU
SRMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvtTWM2OD1yLkCxNlM2KM7:TR?=NVX0OXl1W0GQR1XS
SNG-MMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fTWWlEPTB;MD6wNVMyPyEQvF2=NUDnVVZJW0GQR1XS
CAL-12TM4H6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDMTWM2OD1yLkCxN|Q3KM7:TR?=MWLTRW5ITVJ?
HSC-3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLqdllwUUN3ME2wMlAyOzV3IN88US=>MYLTRW5ITVJ?
DOHH-2M1XDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTBwMEG0NVIh|ryPMl:5V2FPT0WU
NB69NFrCOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTBwMEG1OlUh|ryPMV7TRW5ITVJ?
LC-2-adMkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\Od5dEUUN3ME2wMlAyPThzIN88US=>NG\1WlZUSU6JRWK=
RVH-421NHXxbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjRUndRUUN3ME2wMlAyPjd2IN88US=>MXXTRW5ITVJ?
TGWM3;GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DoPGlEPTB;MD6wNVc{QSEQvF2=M{TBWHNCVkeHUh?=
HCC1569NIPoNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjYXHFKUUN3ME2wMlAyPzl5IN88US=>Mn;KV2FPT0WU
CAL-85-1NFvpOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTBwMEG4N|Ih|ryPNWHyRYdjW0GQR1XS
RPMI-8402MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELLVHhKSzVyPUCuNFE5PThizszNMlTWV2FPT0WU
THP-1M2ntPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTBwMEG5PVgh|ryPNFP6UopUSU6JRWK=
ONS-76NX7YNIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfqTWM2OD1yLkCyNFM3KM7:TR?=MYrTRW5ITVJ?
A2780NF\FRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIqwdoFKSzVyPUCuNFIxPzlizszNNHnxdpBUSU6JRWK=
RPMI-2650NUS1[YxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnSfFM5UUN3ME2wMlAzOjl4IN88US=>NHfJXW9USU6JRWK=
MEL-HOM3P1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{iyS2lEPTB;MD6wNlM1QCEQvF2=M3jwNnNCVkeHUh?=
MC-CARMkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTBwMEKzOVYh|ryPMlvBV2FPT0WU
HSC-2Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwMEK0OlYh|ryPNHnHXllUSU6JRWK=
MEL-JUSONIm5e21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1v2dWlEPTB;MD6wNlQ4OyEQvF2=M4GzTXNCVkeHUh?=
CAL-62MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXmTWM2OD1yLkCyOlAzKM7:TR?=NFfEWY9USU6JRWK=
DMS-273M4ftTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTBwMEK4OFch|ryPMXPTRW5ITVJ?
S-117NVXwPFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rodmlEPTB;MD6wNlkxPiEQvF2=NVe0RWg6W0GQR1XS
SUP-T1M1;rOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjWfJJKSzVyPUCuNFI6PDlizszNMWPTRW5ITVJ?
MZ2-MELNWjoSZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfHTWM2OD1yLkCyPVU6KM7:TR?=NGPYfVVUSU6JRWK=
KYSE-270Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzSO4lwUUN3ME2wMlAzQTd4IN88US=>NWTjV2FyW0GQR1XS
CMKMoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDGTWM2OD1yLkCzNFI{KM7:TR?=NIrqbnpUSU6JRWK=
8505CNWPOSGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTBwMEOwOEDPxE1?M2rQV3NCVkeHUh?=
NUGC-3NXrlZpc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2i2S2lEPTB;MD6wN|A1QCEQvF2=M4rTXXNCVkeHUh?=
A101DMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moi1TWM2OD1yLkCzNFU2KM7:TR?=NIXMbZRUSU6JRWK=
G-401M{DFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTBwMEOwPVMh|ryPM3;4XnNCVkeHUh?=
OVCAR-8NH;VWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\ZTWM2OD1yLkCzNVA4KM7:TR?=MlH2V2FPT0WU
IMR-5NFjVT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PzPWlEPTB;MD6wN|I1PCEQvF2=MYDTRW5ITVJ?
DoTc2-4510NH;3[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfoOJVzUUN3ME2wMlA{Ozl|IN88US=>MYfTRW5ITVJ?
HOSMkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjI[VU1UUN3ME2wMlA{PDd|IN88US=>MWjTRW5ITVJ?
HEC-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoW0TWM2OD1yLkCzOlgh|ryPNUXXb3gyW0GQR1XS
SW756M{HGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7hTWM2OD1yLkCzPFIyKM7:TR?=NV\XUWdjW0GQR1XS
NCI-H64NHnReGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGWxZoFKSzVyPUCuNFM5PDJizszNM{PWS3NCVkeHUh?=
EW-16MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXVb4JKUUN3ME2wMlA{QTB7IN88US=>NYnBU|FwW0GQR1XS
CAL-51MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTBwMESwNFUh|ryPNXu2WWhGW0GQR1XS
KYSE-150NWnPOoYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTBwMESwNVEh|ryPM3zybXNCVkeHUh?=
SW1710NWfuTHBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTBwMESwNVgh|ryPM4rX[HNCVkeHUh?=
HuP-T4MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPJb3J6UUN3ME2wMlA1OTF6IN88US=>MlLwV2FPT0WU
LB373-MEL-DNHXsendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fl[WlEPTB;MD6wOFI{OiEQvF2=MmPDV2FPT0WU
EW-13M37pXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vDfmlEPTB;MD6wOFQxPiEQvF2=MlrZV2FPT0WU
HT-29MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PJemlEPTB;MD6wOFQ6KM7:TR?=NXjmWXRDW0GQR1XS
SCC-25NYjjRXV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTBwMES0PVQh|ryPNH;SeY1USU6JRWK=
REHMnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfrTWM2OD1yLkC0OlM2KM7:TR?=NFT1XWxUSU6JRWK=
L-363NWfmempYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLpTWVKSzVyPUCuNFQ3PzlizszNNWC3PHZxW0GQR1XS
NCI-H1770MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjOcJdKSzVyPUCuNFQ3QTdizszNNH\XWZdUSU6JRWK=
CHL-1NWHrN3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTBwMES4OVch|ryPMV;TRW5ITVJ?
ES1NIHCeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTBwMES4PFUh|ryPNYnpXIdGW0GQR1XS
SCC-15NG\NNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTBwMES5NFIh|ryPM{jo[XNCVkeHUh?=
MRK-nu-1M4HDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY[xRWJEUUN3ME2wMlA1QTN4IN88US=>NHrSTppUSU6JRWK=
PF-382NFnmPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHvR5RPUUN3ME2wMlA1QTN7IN88US=>M2GzXXNCVkeHUh?=
COLO-680NM1uyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTBwMEWwOFch|ryPMn[wV2FPT0WU
LK-2NIKyS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwMEWwOlMh|ryPM3fE[3NCVkeHUh?=
NCI-H2342M{DmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2npcGlEPTB;MD6wOVEyPyEQvF2=NHvFOI1USU6JRWK=
HMV-IINGPL[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\zXmdKSzVyPUCuNFUzOzlizszNNEXHV5BUSU6JRWK=
PC-14MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\COYNKUUN3ME2wMlA2OjV{IN88US=>NUT2TnE3W0GQR1XS
COLO-320-HSRMlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vSSGlEPTB;MD6wOVI5QSEQvF2=MV;TRW5ITVJ?
697NI\Z[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHEW|hKSzVyPUCuNFU{OjNizszNNX;JWWxGW0GQR1XS
NEC8M17JT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTBwMEW1PUDPxE1?NF\TeFRUSU6JRWK=
LCLC-97TM1Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTBwMEW1PVQh|ryPNUP5VZpQW0GQR1XS
DaoyNIPPbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nZNGlEPTB;MD6wOVYyPiEQvF2=NYXOUYdFW0GQR1XS
ETK-1NEPZcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTBwMEW2O|Ih|ryPMXXTRW5ITVJ?
A388M1ruT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17UNWlEPTB;MD6wOVY6PSEQvF2=M4W3[3NCVkeHUh?=
COLO-205NGXYbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrWTWM2OD1yLkC1O|E3KM7:TR?=M1rucXNCVkeHUh?=
SK-PN-DWMm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvQVlNKSzVyPUCuNFU4OjlizszNMX;TRW5ITVJ?
SF268MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7ZcJV3UUN3ME2wMlA2PzV4IN88US=>NWT1VIpYW0GQR1XS
OCI-AML2MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HhbmlEPTB;MD6wOVc4PyEQvF2=MkLIV2FPT0WU
GAMGNGPvdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvGXWpKSzVyPUCuNFU5KM7:TR?=NIruZ5dUSU6JRWK=
BCPAPNYe0d|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7kSVFKSzVyPUCuNFU5QTJizszNMn23V2FPT0WU
BC-1NXP2bYFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLY[WhKSzVyPUCuNFYxOjJizszNMnPFV2FPT0WU
IA-LMM2DmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknuTWM2OD1yLkC2NFU{KM7:TR?=MVrTRW5ITVJ?
NCI-H1299NFnCVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHZVlhKSzVyPUCuNFYyOyEQvF2=NIfCSZZUSU6JRWK=
COR-L23NELV[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIP6cZhKSzVyPUCuNFYyOzRizszNNHfwfYtUSU6JRWK=
KYSE-180M2fh[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTBwME[xOFIh|ryPMmXaV2FPT0WU
LOXIMVINFXvdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonNTWM2OD1yLkC2NVg5KM7:TR?=NIX4NJNUSU6JRWK=
BL-41MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPScFh[UUN3ME2wMlA3OjF7IN88US=>M3Tj[3NCVkeHUh?=
BL-70M{i3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTBwME[zNFIh|ryPNFzWOpBUSU6JRWK=
NOS-1MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jjfGlEPTB;MD6wOlQyOSEQvF2=NGjuSoJUSU6JRWK=
NB13MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4ewNWlEPTB;MD6wOlQzOSEQvF2=NIrpdJJUSU6JRWK=
CAL-27NIHGWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTBwME[0OlQh|ryPNIjFSHZUSU6JRWK=
CA46NYjI[WRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\4c3NWUUN3ME2wMlA3PTN5IN88US=>NWfMTWtOW0GQR1XS
SW962M2OweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;oSHpIUUN3ME2wMlA3PTZ7IN88US=>NUf6[GtrW0GQR1XS
NCI-H226NUPaVYFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HwNGlEPTB;MD6wOlY{OiEQvF2=M{TndXNCVkeHUh?=
KYSE-70NYXST4ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTBwME[5OFUh|ryPNUX4cXlFW0GQR1XS
DaudiMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTXPZVRUUN3ME2wMlA4ODhzIN88US=>MlfpV2FPT0WU
SW626NX3qfnVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFr4fpdKSzVyPUCuNFczODRizszNM2TtRXNCVkeHUh?=
ESS-1M1TIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzk[mRKSzVyPUCuNFczPDZizszNNW\TOo5vW0GQR1XS
YTM3fi[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTBwMEezOFUh|ryPNWfLPZBwW0GQR1XS
P12-ICHIKAWAMmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3X6ZmlEPTB;MD6wO|M1QSEQvF2=MlzyV2FPT0WU
BxPC-3MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrnNIlJUUN3ME2wMlA4PDV6IN88US=>NVXoeG8zW0GQR1XS
CTV-1NEO4XlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwMEe1NVch|ryPMlr1V2FPT0WU
MLMAM1;ld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPyO2pvUUN3ME2wMlA4PTN2IN88US=>Mk\XV2FPT0WU
WSU-NHLMoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnsbI1UUUN3ME2wMlA4PTV2IN88US=>NFzuOoJUSU6JRWK=
CTB-1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjDdYI6UUN3ME2wMlA4PTh6IN88US=>MXXTRW5ITVJ?
MMAC-SFMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjkWldKSzVyPUCuNFc3PjhizszNMoP0V2FPT0WU
8-MG-BAMmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTBwMEe4NFEh|ryPMlXJV2FPT0WU
NCI-H358M{LwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEH3b|BKSzVyPUCuNFc5PzlizszNNWjlTFEyW0GQR1XS
BFTC-905MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrKNYx2UUN3ME2wMlA4QTB7IN88US=>MmfPV2FPT0WU
NCI-H727NXO5fmZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfCUI9KSzVyPUCuNFgxPTNizszNM4n2c3NCVkeHUh?=
CHP-212NGnxPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLPTWM2OD1yLkC4NFk2KM7:TR?=NWjlTmw{W0GQR1XS
HOP-62M3jSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjiTWM2OD1yLkC4NlQ2KM7:TR?=NVTV[HE6W0GQR1XS
CESSNVL4XpdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfHZZZKSzVyPUCuNFgzPjlizszNMV7TRW5ITVJ?
HuCCT1M2XYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTBwMEizN|Mh|ryPNF2ze3pUSU6JRWK=
DELNXXLd5ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfjV2lKSzVyPUCuNFg{PDdizszNNXWwdYZKW0GQR1XS
5637MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwMEizOlch|ryPMlnFV2FPT0WU
RS4-11MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnJb4ZKSzVyPUCuNFg1QTdizszNNIe2WVhUSU6JRWK=
KURAMOCHIMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nHOWlEPTB;MD6wPFUxQSEQvF2=MoXiV2FPT0WU
A427MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXp[IVKSzVyPUCuNFg2OTJizszNNH\OVXNUSU6JRWK=
A3-KAWNI\6elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETLS|dKSzVyPUCuNFg2PjZizszNMnTOV2FPT0WU
LS-123M{f0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;wPGlEPTB;MD6wPFcyQSEQvF2=MlWzV2FPT0WU
LoVoMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXnTWM2OD1yLkC4O|Ih|ryPNEe0cGZUSU6JRWK=
PA-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHB[nJKSzVyPUCuNFg4PjlizszNMlr4V2FPT0WU
CP50-MEL-BNIf4Z|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3JVYhKSzVyPUCuNFg4QTNizszNM3\ocHNCVkeHUh?=
A431MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwMEi4NFEh|ryPNHPGTIpUSU6JRWK=
HCT-116MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTPbJZKSzVyPUCuNFg5ODJizszNMWnTRW5ITVJ?
A4-FukM4jMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\keWZlUUN3ME2wMlA5QTR5IN88US=>MVzTRW5ITVJ?
RPMI-6666MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;QS2pwUUN3ME2wMlA5QTZ5IN88US=>MlrIV2FPT0WU
Calu-6MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwMEmwNlkh|ryPNIG4c5RUSU6JRWK=
KMOE-2NV7yWYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7Jd3dNUUN3ME2wMlA6ODN7IN88US=>MonwV2FPT0WU
A704MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\jOWxKSzVyPUCuNFkyPSEQvF2=NXzxOItiW0GQR1XS
HO-1-N-1NH\a[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInGZ5BKSzVyPUCuNFkzPDlizszNMoKzV2FPT0WU
NCI-H2122NWXpNYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXywR2N3UUN3ME2wMlA6Ozd6IN88US=>Ml\oV2FPT0WU
U-698-MNGK2TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTUTWM2OD1yLkC5OFA6KM7:TR?=MWTTRW5ITVJ?
IST-SL2M1iwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwMEm0Olgh|ryPNVnteW4yW0GQR1XS
TE-10NV\udYExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnRWZI1UUN3ME2wMlA6PTh2IN88US=>NUfPN|BEW0GQR1XS
PANC-03-27MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2OwXGlEPTB;MD6wPVY4OSEQvF2=NXvDb2U2W0GQR1XS
KYSE-410NWfVPWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkf5TWM2OD1yLkC5O|k4KM7:TR?=MkT0V2FPT0WU
TE-8MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTCSJVKSzVyPUCuNFk5QDVizszNMnvEV2FPT0WU
MN-60MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3GyU2lEPTB;MD6wPVg6PyEQvF2=Mn3qV2FPT0WU
NCI-H460NWfrTJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2C0XGlEPTB;MD6xNFA6KM7:TR?=NEDjUpZUSU6JRWK=
LB771-HNCM4rkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLVeXRKSzVyPUCuNVAzPTVizszNM1fBbHNCVkeHUh?=
ES4NIntSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfnXFRoUUN3ME2wMlExOjZ2IN88US=>MojmV2FPT0WU
HUTU-80NFrzOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfWTWM2OD1yLkGwN|Y2KM7:TR?=MmPTV2FPT0WU
647-VNVm5OGJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\6TWxEUUN3ME2wMlExPDB6IN88US=>NWP6OWh3W0GQR1XS
HTC-C3NFHFV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHMXIVKSzVyPUCuNVA1OzJizszNNVS3fJdNW0GQR1XS
NTERA-S-cl-D1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDWTWM2OD1yLkGwOFQ5KM7:TR?=NInwco9USU6JRWK=
A2058M2jVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3exVmlEPTB;MD6xNFY2PSEQvF2=NV3B[3VjW0GQR1XS
MZ1-PCMoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwMUC4N{DPxE1?Mn3pV2FPT0WU
J82MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;keGNKSzVyPUCuNVA5QDRizszNM4rEWHNCVkeHUh?=
ARH-77M3TCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v6emlEPTB;MD6xNUDPxE1?NVXTV4FZW0GQR1XS
Ca9-22NIO0Z2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;Lc2xiUUN3ME2wMlEyOTJ6IN88US=>Mk\3V2FPT0WU
NCI-H1648NUHTT3V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PGeWlEPTB;MD6xNVI5PiEQvF2=MXnTRW5ITVJ?
MC116NInodpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3E[Hd[UUN3ME2wMlEyOzN5IN88US=>MmjJV2FPT0WU
EoL-1-cellMmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;TTWM2OD1yLkGxOFY4KM7:TR?=NFfxUpZUSU6JRWK=
PANC-10-05MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;DTWM2OD1yLkGxOFkyKM7:TR?=M1HXcHNCVkeHUh?=
SF539M1LWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHDTFJKSzVyPUCuNVE3OTZizszNM3XkR3NCVkeHUh?=
ES8NWPIcpA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrv[lNKSzVyPUCuNVE3OzNizszNNVHKU4NOW0GQR1XS
NCI-H810NXWwV|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTUTWM2OD1yLkGxOlY1KM7:TR?=MlXMV2FPT0WU
J-RT3-T3-5MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PodmlEPTB;MD6xNVc2KM7:TR?=M4HiZ3NCVkeHUh?=
NYM1L3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmOyTWM2OD1yLkGxPFE4KM7:TR?=NWfqS5o3W0GQR1XS
NCI-SNU-1M2ezfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlz2TWM2OD1yLkGyNVQ5KM7:TR?=M33QXXNCVkeHUh?=
EFM-19NUm2N3c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTBwMUKzO|Qh|ryPM2nte3NCVkeHUh?=
HCC1806MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTBwMUKzPFMh|ryPMVHTRW5ITVJ?
HCE-TNGntXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\RTWM2OD1yLkGyOVMyKM7:TR?=MYjTRW5ITVJ?
HT-1376NWOxdpdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TxdmlEPTB;MD6xNlY3QCEQvF2=MX;TRW5ITVJ?
BE-13MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVS3WFU3UUN3ME2wMlEzQDZ4IN88US=>M1O3Z3NCVkeHUh?=
NCI-H520NFiyb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlqxTWM2OD1yLkGyPFY4KM7:TR?=MUjTRW5ITVJ?
SK-MES-1NFqyUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTBwMUK5NVMh|ryPMlnVV2FPT0WU
SNU-423Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTBwMUK5NVQh|ryPMVPTRW5ITVJ?
Ramos-2G6-4C10NHjjem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3G4SGlEPTB;MD6xNlkyPiEQvF2=MV\TRW5ITVJ?
EW-18MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWGyNIp5UUN3ME2wMlE{ODJ4IN88US=>MkKzV2FPT0WU
NCI-H2087MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInhZ5lKSzVyPUCuNVMxOjdizszNNFzJdlJUSU6JRWK=
COLO-792NVPldVZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTBwMUOxOlUh|ryPNYLDfGR6W0GQR1XS
QIMR-WILNFvpS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\aVmlEPTB;MD6xN|IzOyEQvF2=M3vVcHNCVkeHUh?=
ACHNNHf0emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLWb|NKSzVyPUCuNVMzPDdizszNM{T1[HNCVkeHUh?=
RPMI-8866MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TSOWlEPTB;MD6xN|I3OSEQvF2=NG\TbWVUSU6JRWK=
SK-LU-1MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7JTWM2OD1yLkGzOFQ6KM7:TR?=MmnJV2FPT0WU
SK-UT-1M4Lq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTBwMUO2Nlgh|ryPNXPFdZBGW0GQR1XS
MFE-296NFj2cpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTBwMUO4OlQh|ryPM3z3dnNCVkeHUh?=
RDMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rqZWlEPTB;MD6xN|k6PyEQvF2=NHLOUmdUSU6JRWK=
LS-411NMmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7rSYFKSzVyPUCuNVQzQTVizszNM2rSfXNCVkeHUh?=
NCI-H747MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XXfGlEPTB;MD6xOFMh|ryPNVnS[HVNW0GQR1XS
ES6MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LzPGlEPTB;MD6xOFM3KM7:TR?=NX\aWHdzW0GQR1XS
TE-1NHPDSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXYTWM2OD1yLkG0OFA4KM7:TR?=NHjZdWNUSU6JRWK=
SJSA-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTBwMUS3NFch|ryPM2LUXXNCVkeHUh?=
NCI-H1355M2K3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mli0TWM2OD1yLkG1Nlk{KM7:TR?=NWTBSJhQW0GQR1XS
HELMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLGTWM2OD1yLkG1OFQ4KM7:TR?=M1rvcXNCVkeHUh?=
639-VMlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjJPWFKSzVyPUCuNVU2QTZizszNM2DTV3NCVkeHUh?=
AN3-CAMnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwMUW2N|kh|ryPM3HBenNCVkeHUh?=
SK-MEL-2NW\vUFg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLCTWM2OD1yLkG1OlY5KM7:TR?=M2K2OXNCVkeHUh?=
SW872NIjUOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHe2TlJKSzVyPUCuNVYxPDJizszNMX\TRW5ITVJ?
DU-4475NEnnb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDhU3liUUN3ME2wMlE3OTZ{IN88US=>MVrTRW5ITVJ?
YKG-1MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoK1TWM2OD1yLkG2Nlc{KM7:TR?=Ml74V2FPT0WU
GT3TKBNInOcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XxfmlEPTB;MD6xOlI5OyEQvF2=NWr3NWxQW0GQR1XS
GB-1NIHjZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHNTWM2OD1yLkG2OFI1KM7:TR?=NF\J[WtUSU6JRWK=
KARPAS-422NV33Tml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTBwMU[1O|Qh|ryPMYrTRW5ITVJ?
ATN-1M1zVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmP0TWM2OD1yLkG2OlU3KM7:TR?=NVXCSXhnW0GQR1XS
HLENHPCRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTBwMU[4O|ch|ryPMoK3V2FPT0WU
D-542MGMoe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVm1XFZLUUN3ME2wMlE3QTh4IN88US=>NGLFc|NUSU6JRWK=
EB-3MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;pUGlEPTB;MD6xO|MyKM7:TR?=M2DOfXNCVkeHUh?=
HCC1143NYr3fmpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fxXmlEPTB;MD6xO|M6PiEQvF2=MU\TRW5ITVJ?
DJM-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LYN2lEPTB;MD6xO|Q2OSEQvF2=M3GyVHNCVkeHUh?=
BT-474MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYOwT3FbUUN3ME2wMlE4PDh7IN88US=>NFr1T2ZUSU6JRWK=
BB65-RCCNHH1SYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3HcGY5UUN3ME2wMlE4PTR3IN88US=>MonXV2FPT0WU
NCI-H292NYXuW4s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{O5fmlEPTB;MD6xO|YxOSEQvF2=M3rnZ3NCVkeHUh?=
MKN28M{iyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXBW5VNUUN3ME2wMlE4PjV|IN88US=>MmLHV2FPT0WU
TK10M4\pdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13iU2lEPTB;MD6xO|cxOiEQvF2=NH\Od2dUSU6JRWK=
TYK-nuNFHPT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17KPWlEPTB;MD6xO|k1QSEQvF2=NFHBe3BUSU6JRWK=
8305CM4XhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NICwRmlKSzVyPUCuNVc6PzFizszNM{G3UnNCVkeHUh?=
MV-4-11M4T6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPVTWM2OD1yLkG3PVc4KM7:TR?=NFXneVVUSU6JRWK=
NCI-H522NV3YOoU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzkNVd5UUN3ME2wMlE5ODl2IN88US=>M3vZRXNCVkeHUh?=
Hs-578-TMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1u0U2lEPTB;MD6xPFI6OiEQvF2=NXrROmN6W0GQR1XS
LCLC-103HNHfQNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHn1SIhKSzVyPUCuNVg2OjdizszNM3K3cHNCVkeHUh?=
MHH-ES-1M2PkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml31TWM2OD1yLkG4OlI6KM7:TR?=M1fqT3NCVkeHUh?=
NCI-H441NV;Y[Jg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTwSFZlUUN3ME2wMlE6OTR6IN88US=>NVj2VlVWW0GQR1XS
AM-38MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY[yPGJEUUN3ME2wMlE6OjJ3IN88US=>NGG2V2xUSU6JRWK=
SW1783NGHBRm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLyU|F3UUN3ME2wMlE6OzB3IN88US=>Mn7DV2FPT0WU
SK-HEP-1NWjpOYJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Lx[2lEPTB;MD6xPVY{PyEQvF2=NY\0eopyW0GQR1XS
OAW-28M3jrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XUOWlEPTB;MD6yNFE4QCEQvF2=M4PS[XNCVkeHUh?=
TE-15MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Kx[GlEPTB;MD6yNFI2OiEQvF2=NF;R[ZBUSU6JRWK=
HCE-4NXK5O2NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTUfHFZUUN3ME2wMlIxOjh2IN88US=>MkHFV2FPT0WU
JiyoyeP-2003MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjpVlU1UUN3ME2wMlIxOzN4IN88US=>Mm\uV2FPT0WU
OVCAR-4MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfLfpdIUUN3ME2wMlIxPjJ6IN88US=>NVzCbIE6W0GQR1XS
SNU-449NEfiXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDiTWM2OD1yLkKwO|k4KM7:TR?=MYLTRW5ITVJ?
SBC-5NYXjRXRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zIb2lEPTB;MD6yNVIyPSEQvF2=M3HaRXNCVkeHUh?=
T84MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;2[mlEPTB;MD6yNVI1QCEQvF2=NF7iWY1USU6JRWK=
LP-1M1\3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\mO5hKSzVyPUCuNlE{ODJizszNMYfTRW5ITVJ?
MG-63MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jQ[2lEPTB;MD6yNVM5OiEQvF2=NGrnRZZUSU6JRWK=
OAW-42M4DXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1z3bWlEPTB;MD6yNVQ4QCEQvF2=MWPTRW5ITVJ?
L-540MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnNTWM2OD1yLkKxOVk5KM7:TR?=NHHDXFBUSU6JRWK=
RH-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwMkKyOFIh|ryPMUDTRW5ITVJ?
HCT-15NInE[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnoSmVKSzVyPUCuNlI1QDRizszNNHLreGxUSU6JRWK=
OCUB-MNWLve4lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nLfmlEPTB;MD6yNlQ5QCEQvF2=M4DnZnNCVkeHUh?=
GP5dNWDY[5h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfWdZJJUUN3ME2wMlIzPTJ6IN88US=>M3nsUHNCVkeHUh?=
NCI-H2030NXjkdXBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTBwMkK3N|Qh|ryPMUXTRW5ITVJ?
ML-2M{PDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITG[mdKSzVyPUCuNlI5QDlizszNNHLQZ4tUSU6JRWK=
CAL-39MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlmzTWM2OD1yLkKyPVM3KM7:TR?=MnexV2FPT0WU
MIA-PaCa-2MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DmVmlEPTB;MD6yN|I5PyEQvF2=MlnZV2FPT0WU
TE-9MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\F[2pKSzVyPUCuNlM{OiEQvF2=MnHLV2FPT0WU
LB2518-MELMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXz5dnpNUUN3ME2wMlI{Ozd{IN88US=>NEnZSm1USU6JRWK=
DBNVq3UFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDpTWM2OD1yLkKzOFM5KM7:TR?=M{XsSHNCVkeHUh?=
NCI-H596Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LDW2lEPTB;MD6yN|U4OSEQvF2=NVLXbZFkW0GQR1XS
SW1990NEHEW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXZTWM2OD1yLkKzPVQ3KM7:TR?=M{DrTHNCVkeHUh?=
P30-OHKNEHJWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP6TWM2OD1yLkK0NFUh|ryPNFzj[VRUSU6JRWK=
ALL-PONILufVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEmybVBKSzVyPUCuNlQyPjlizszNMl\EV2FPT0WU
Saos-2MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LVNGlEPTB;MD6yOFU4OSEQvF2=NGX0RYRUSU6JRWK=
MFH-inoM3:2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\sTWM2OD1yLkK0OlkzKM7:TR?=MlrOV2FPT0WU
OE33NHjXdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE[2XWlKSzVyPUCuNlUyOSEQvF2=MWLTRW5ITVJ?
Calu-3MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTiR|BKSzVyPUCuNlUzQTdizszNM1r5SXNCVkeHUh?=
HTM{XnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfzTWM2OD1yLkK1OlIyKM7:TR?=MoDqV2FPT0WU
LXF-289MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\FeGlEPTB;MD6yOVk5PCEQvF2=MnThV2FPT0WU
KGNNYSxT2F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\CfWlEPTB;MD6yOlA5QSEQvF2=MVPTRW5ITVJ?
NCI-H1417NIG4SIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2G1W2lEPTB;MD6yOlUzPCEQvF2=MYfTRW5ITVJ?
SF126MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwMkezNFIh|ryPM2C0ZXNCVkeHUh?=
SASM{nCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TXWGlEPTB;MD6yO|MxQCEQvF2=NV7Zd3k4W0GQR1XS
22RV1NF\QbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\BdGJKSzVyPUCuNlc{PzhizszNNUDz[5YyW0GQR1XS
GI-1MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHW5VnVKSzVyPUCuNlc1QDdizszNNGW2bXlUSU6JRWK=
ES3MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVq1ZYc4UUN3ME2wMlI4PzZ|IN88US=>NYi4dXBDW0GQR1XS
NB1NV;hW2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlL4TWM2OD1yLkK3PFc3KM7:TR?=M1zD[3NCVkeHUh?=
NCI-H650M3jK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vFN2lEPTB;MD6yPFMxOiEQvF2=M1XGU3NCVkeHUh?=
IST-MES1M2nIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\RTWM2OD1yLkK4OVU1KM7:TR?=NUHPOJVJW0GQR1XS
UM-UC-3MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfhTWM2OD1yLkK5NVQh|ryPNH3xdnRUSU6JRWK=
CAL-120NVroSHpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTBwMkm2N|Eh|ryPMlrRV2FPT0WU
UACC-62MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwM{CyOFEh|ryPMVnTRW5ITVJ?
TE-11MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTBwM{CyOFkh|ryPMm\lV2FPT0WU
MKN1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTBwM{CzOkDPxE1?M2DwcXNCVkeHUh?=
KS-1NYLEfm9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjFSWRLUUN3ME2wMlMxPTJ4IN88US=>MYnTRW5ITVJ?
GCIYMoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjkZlNKSzVyPUCuN|ExODJizszNMlO2V2FPT0WU
OVCAR-5MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXLTWM2OD1yLkOxNVA3KM7:TR?=MluyV2FPT0WU
U-266MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmi1TWM2OD1yLkOxNVQ4KM7:TR?=NETaWFRUSU6JRWK=
Calu-1NEi3S5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mly1TWM2OD1yLkOxNlg6KM7:TR?=MYrTRW5ITVJ?
SK-LMS-1MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTXTWM2OD1yLkOxOFI6KM7:TR?=NHzMUmFUSU6JRWK=
COLO-741NIm3R4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwM{G2NVQh|ryPNIDaZnZUSU6JRWK=
RPMI-8226NIDUc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPlRmZtUUN3ME2wMlMyPjRzIN88US=>MkTZV2FPT0WU
KM12M3TUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzSVlVKSzVyPUCuN|E5OyEQvF2=MkHzV2FPT0WU
NMC-G1NXXBVGVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnJTWM2OD1yLkOxPFYh|ryPMXLTRW5ITVJ?
SJRH30NWjDXI1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWS4NWhRUUN3ME2wMlMzODV{IN88US=>NIKxdXJUSU6JRWK=
COR-L105MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPJWWpmUUN3ME2wMlMzOjF6IN88US=>M{X5eXNCVkeHUh?=
IM-9Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DlRmlEPTB;MD6zN|AzOSEQvF2=NHe4NHBUSU6JRWK=
TE-12NFXZb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MluzTWM2OD1yLkOzN|E4KM7:TR?=MofnV2FPT0WU
KG-1NEnzSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTBwM{O0N|Ih|ryPNWPEepp5W0GQR1XS
U251MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTMTWM2OD1yLkOzOFU3KM7:TR?=M1XSWnNCVkeHUh?=
EFO-27NFr4fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjZepdKSzVyPUCuN|M6PTFizszNMkDZV2FPT0WU
EW-24M4nVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2npRmlEPTB;MD6zN|k5PCEQvF2=M13l[nNCVkeHUh?=
SF295NHf4e5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XFR2lEPTB;MD6zN|k6QSEQvF2=M1HiRXNCVkeHUh?=
MC-IXCNVXvTYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPrTWM2OD1yLkO0OUDPxE1?MXnTRW5ITVJ?
NCI-H2405M1nmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1voOmlEPTB;MD6zOFc{OiEQvF2=NXHoN3hFW0GQR1XS
NCI-H2009MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{K2d2lEPTB;MD6zOFc{QSEQvF2=MVjTRW5ITVJ?
LB1047-RCCNUT2d4c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXCTWM2OD1yLkO1PFE2KM7:TR?=M2D1Z3NCVkeHUh?=
KNS-81-FDNFnR[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTBwM{[2Olch|ryPMnfRV2FPT0WU
HOP-92MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2O4XmlEPTB;MD6zOlg{KM7:TR?=MX;TRW5ITVJ?
L-428MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTBwM{ewNVYh|ryPMl7UV2FPT0WU
C3AMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPDNYZKSzVyPUCuN|c{PzlizszNM2HleXNCVkeHUh?=
NCI-H1792NUPofph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkC0TWM2OD1yLkO3OlU2KM7:TR?=NGXHbm5USU6JRWK=
HuH-7MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHrNXJKSzVyPUCuN|c6OSEQvF2=M{PhUHNCVkeHUh?=
AGSNVHnZW1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrVTWM2OD1yLkO4OlM5KM7:TR?=NF3EOJRUSU6JRWK=
HT-1197NF7VUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnMTpZTUUN3ME2wMlM6PDZizszNNIPZUo9USU6JRWK=
CGTH-W-1M3;IXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHy3WmNKSzVyPUCuN|k6OTNizszNNXTTSlZRW0GQR1XS
KNS-42NWLmNopET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7FTWM2OD1yLkSwNFQ2KM7:TR?=M1LoSHNCVkeHUh?=
HuO-3N1MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HmVGlEPTB;MD60NFA2PSEQvF2=MlzVV2FPT0WU
VMRC-RCZM1TvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTBwNECzNFMh|ryPMorMV2FPT0WU
SW954MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfmbFhKSzVyPUCuOFA{OzVizszNNUCzfY44W0GQR1XS
MES-SAM{PHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HmVmlEPTB;MD60NFUxPSEQvF2=MXjTRW5ITVJ?
Ca-SkiMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nEV2lEPTB;MD60NFUzPCEQvF2=M{XjXnNCVkeHUh?=
SW13M33URWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrQTWM2OD1yLkSwOlI3KM7:TR?=M{e4THNCVkeHUh?=
NCI-H1437NETyNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jOSmlEPTB;MD60NFgxPSEQvF2=Mk\0V2FPT0WU
U-118-MGM2DhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjEUlhCUUN3ME2wMlQxQTB2IN88US=>M2LGcHNCVkeHUh?=
NCI-H1734NXe5SIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTW[4lMUUN3ME2wMlQzODF|IN88US=>MnjHV2FPT0WU
HDLM-2NFHWbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;OflRKSzVyPUCuOFIxOzNizszNNF3EcXBUSU6JRWK=
AU565Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLIdFNCUUN3ME2wMlQzPDZ6IN88US=>MWLTRW5ITVJ?
FADUNHzjOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTBwNEK2OFkh|ryPM1rR[XNCVkeHUh?=
OS-RC-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTBwNEOwPFMh|ryPNFXXdo9USU6JRWK=
CAMA-1NEiy[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nNfmlEPTB;MD60N|YzPiEQvF2=M2jYPHNCVkeHUh?=
MONO-MAC-6MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDaVoRHUUN3ME2wMlQ{QDR7IN88US=>NEXJWoFUSU6JRWK=
LB831-BLCNGfKR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPSTWM2OD1yLkS0N|cyKM7:TR?=M13TfXNCVkeHUh?=
SW982MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LMdGlEPTB;MD60OFUzQCEQvF2=NYHCUIF4W0GQR1XS
SCC-3MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDpTWM2OD1yLkS0OVc6KM7:TR?=NGrtXXNUSU6JRWK=
C32NWLDd3N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofNTWM2OD1yLkS1NlI6KM7:TR?=MWXTRW5ITVJ?
BFTC-909NWLoeVZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2K3[2lEPTB;MD60OVI6QSEQvF2=MYHTRW5ITVJ?
MEG-01NUTSNVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fKTmlEPTB;MD60OVM4OyEQvF2=MUDTRW5ITVJ?
M14MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTBwNEW5O|kh|ryPMV7TRW5ITVJ?
MPP-89MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXywNG1HUUN3ME2wMlQ3OjV4IN88US=>MWXTRW5ITVJ?
HCC1937Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jvSGlEPTB;MD60OlM5PCEQvF2=M2[yNHNCVkeHUh?=
SW837M3HCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4exWmlEPTB;MD60OlczOiEQvF2=MUPTRW5ITVJ?
DU-145MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTBwNE[3Nlkh|ryPMnyxV2FPT0WU
LB996-RCCM1;zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwNEewOVQh|ryPMWfTRW5ITVJ?
C8166NX3TVFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzofYlKSzVyPUCuOFc1KM7:TR?=MnnYV2FPT0WU
MOLT-4MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HUcGlEPTB;MD60O|c{PCEQvF2=M3jKcHNCVkeHUh?=
DMS-53MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmxTWM2OD1yLkS3PFA6KM7:TR?=MXXTRW5ITVJ?
TE-5NVXFW4pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvmTWM2OD1yLkS4N|A2KM7:TR?=M1vpSHNCVkeHUh?=
KYSE-520M2nmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzITWM2OD1yLkS4N|Q{KM7:TR?=NF\ldXRUSU6JRWK=
Detroit562NIS4eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LsZWlEPTB;MD60PFg3KM7:TR?=NF;kTnRUSU6JRWK=
SIMANYr6bWRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fG[mlEPTB;MD60PVQyPyEQvF2=NV3GbJByW0GQR1XS
NCI-H1651NHTSNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mln4TWM2OD1yLkS5Olch|ryPMYHTRW5ITVJ?
HCC1599NV\6ZYNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnYTWM2OD1yLkS5PVU2KM7:TR?=NVzafJl{W0GQR1XS
ABC-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{O3UGlEPTB;MD61NFQ6PiEQvF2=MWHTRW5ITVJ?
CAL-33MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPWTWM2OD1yLkWwPFQ1KM7:TR?=NFG4Nm5USU6JRWK=
OPM-2NGLnVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvHTWM2OD1yLkWwPVM4KM7:TR?=MmrXV2FPT0WU
RPMI-7951MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTKOlNKSzVyPUCuOVA6PTdizszNNF;Ye2JUSU6JRWK=
HT-1080MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;rRmlEPTB;MD61NVEyQSEQvF2=NYP5Sm1HW0GQR1XS
LC4-1M1mwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzTR5lKSzVyPUCuOVE1ODNizszNNYrqR5lvW0GQR1XS
OVCAR-3MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnNO4RrUUN3ME2wMlUyPTdizszNNIDOb21USU6JRWK=
CAPAN-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPjTWM2OD1yLkWyNlg5KM7:TR?=Mn\tV2FPT0WU
SK-OV-3M3ziO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLSdml3UUN3ME2wMlUzPDN2IN88US=>MlLKV2FPT0WU
HuP-T3NFnzZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjaUnlKSzVyPUCuOVI5OjdizszNNFXQ[HZUSU6JRWK=
NCI-H838NFzPPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\MUHRKSzVyPUCuOVI5PDlizszNNHLnSZlUSU6JRWK=
K5NGPoS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHTeWNKSzVyPUCuOVMzODFizszNMXjTRW5ITVJ?
CAL-72NX3vblc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUK5UGY{UUN3ME2wMlU{Ozh5IN88US=>NF3mZ|dUSU6JRWK=
NH-12NWHWe4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PnSmlEPTB;MD61N|k2QSEQvF2=NFrkSW5USU6JRWK=
SNB75MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\sN2hKSzVyPUCuOVU4OyEQvF2=Mk\FV2FPT0WU
BPH-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1noVGlEPTB;MD61OlM1PCEQvF2=NGfF[WpUSU6JRWK=
NOMO-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWGz[nJjUUN3ME2wMlU3Ozd{IN88US=>M1jkOnNCVkeHUh?=
G-402MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTBwNU[0PVkh|ryPNWnRSHZIW0GQR1XS
NCI-H2052MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DDPGlEPTB;MD61Olc1OSEQvF2=MoS2V2FPT0WU
RCM-1NWfEZo5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\Jd2lEPTB;MD61O|E3PiEQvF2=NIfqcW9USU6JRWK=
COR-L279NEX2dnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPWW5FKSzVyPUCuOVcyQDVizszNNFrwUYRUSU6JRWK=
A253M1fDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XUcGlEPTB;MD61O|UzPSEQvF2=M17jPHNCVkeHUh?=
SK-MM-2M1fZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TocGlEPTB;MD61O|Y4QSEQvF2=MonzV2FPT0WU
NCI-H1703NYrsboJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITNSnVKSzVyPUCuOVk1OjdizszNM4TXSnNCVkeHUh?=
UACC-257MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TXUGlEPTB;MD61PVQ5PyEQvF2=NYXjTGQ3W0GQR1XS
KALS-1MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLNUFRKSzVyPUCuOlAxOTFizszNNHj4b5dUSU6JRWK=
ES5MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\J[HprUUN3ME2wMlYxPDhizszNNIHOUpRUSU6JRWK=
MHH-CALL-2NWrzW4RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MluwTWM2OD1yLk[wPFg5KM7:TR?=M1HrWnNCVkeHUh?=
ChaGo-K-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3pVIJsUUN3ME2wMlYyOjJ7IN88US=>NYjMVYJ7W0GQR1XS
TGBC1TKBM2Gwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTkN|FKSzVyPUCuOlE6QCEQvF2=NV[0WFJWW0GQR1XS
KU-19-19MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPSe4o3UUN3ME2wMlY1PTh4IN88US=>MUHTRW5ITVJ?
COLO-684NVnxN3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTBwNkW2NVEh|ryPNUnoNWZYW0GQR1XS
LS-1034NIK0WWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fNcmlEPTB;MD62OVgyQSEQvF2=MVzTRW5ITVJ?
RT-112MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzoTWM2OD1yLk[2OVg4KM7:TR?=NETPfHdUSU6JRWK=
Capan-2NWG2R2NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjaclN4UUN3ME2wMlY3PjJ{IN88US=>MVTTRW5ITVJ?
HSC-4NXjIZmlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzZVW5sUUN3ME2wMlY3Pjl6IN88US=>MX;TRW5ITVJ?
COLO-824NXf2OJhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXKVoVKSzVyPUCuOlc5OjNizszNMYDTRW5ITVJ?
NCI-H2170NV3TN2d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLQU2JtUUN3ME2wMlY5OjV6IN88US=>M33ienNCVkeHUh?=
GDM-1Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjDTWM2OD1yLk[4OFk1KM7:TR?=M3XGb3NCVkeHUh?=
KP-4NYKw[4p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVz2eZFSUUN3ME2wMlY6PTd|IN88US=>M1XMU3NCVkeHUh?=
VA-ES-BJMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTBwNkm5PFYh|ryPMWTTRW5ITVJ?
KM-H2MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrPTWM2OD1yLkewNFkyKM7:TR?=MXPTRW5ITVJ?
HHMmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDtTWM2OD1yLkewOlYzKM7:TR?=M4XvOnNCVkeHUh?=
DK-MGM4HXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPXTWM2OD1yLkexNFE3KM7:TR?=NYLXNnVFW0GQR1XS
VM-CUB-1Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13qemlEPTB;MD63NVI2QSEQvF2=MofuV2FPT0WU
COLO-829NHHlVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1yxXWlEPTB;MD63NVk5PSEQvF2=MVjTRW5ITVJ?
OMC-1NHrPTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3JOohKSzVyPUCuO|IyODRizszNMkXQV2FPT0WU
NB12MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXraPVVzUUN3ME2wMlczPTB2IN88US=>M{DVNnNCVkeHUh?=
NCI-H28M17DXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\ISJA1UUN3ME2wMlc1ODh|IN88US=>MmnxV2FPT0WU
A673NGriWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LhWGlEPTB;MD63OVE4PyEQvF2=MY\TRW5ITVJ?
LB2241-RCCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LoNGlEPTB;MD63OlA5PyEQvF2=M1j1VnNCVkeHUh?=
CCRF-CEMNXHReoh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTBwN{ewOVIh|ryPNV76bplqW0GQR1XS
NCI-H510AMnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTBwN{exPFYh|ryPNH7pSYhUSU6JRWK=
SW48M1m0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTBwN{ezN|Mh|ryPMmX1V2FPT0WU
NCI-H2081MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTBwN{ixOFch|ryPM1vsdnNCVkeHUh?=
RMG-INXjx[Io4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTBwN{iyNVIh|ryPMYjTRW5ITVJ?
LU-99AMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknwTWM2OD1yLke4OFE{KM7:TR?=M4frOXNCVkeHUh?=
KP-N-YSNV\wd49ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;RXIRKSzVyPUCuO|g6OjFizszNMXfTRW5ITVJ?
MDA-MB-231NVfVNpcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonsTWM2OD1yLkiwNVMyKM7:TR?=M4\oeHNCVkeHUh?=
U031NHW2U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWD1R2xiUUN3ME2wMlgyPDJ|IN88US=>NHvue21USU6JRWK=
EVSA-TNWT0[pRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jTemlEPTB;MD64NVY4OiEQvF2=Ml\PV2FPT0WU
MDA-MB-157MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ribWlEPTB;MD64NlI4OSEQvF2=MlHUV2FPT0WU
EHEBNH;0fGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LUT2lEPTB;MD64NlI4PiEQvF2=NIL3WZRUSU6JRWK=
KINGS-1NWKzTZh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTBwOEK1OVUh|ryPM2LRV3NCVkeHUh?=
23132-87MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTBwOEK4OFMh|ryPM4Pl[nNCVkeHUh?=
EFO-21MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTBwOESwPFkh|ryPM1rESHNCVkeHUh?=
DOKMmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkf3TWM2OD1yLki0PEDPxE1?MoTPV2FPT0WU
NCI-H2171MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\FRWlEPTB;MD64OFk3KM7:TR?=NYrjTJNLW0GQR1XS
NCI-SNU-5MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlP1TWM2OD1yLki1OVch|ryPMWXTRW5ITVJ?
SK-N-DZM3uwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTBwOEW5OFMh|ryPM1zIeXNCVkeHUh?=
SNU-C2BNHzlVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVO4XlFmUUN3ME2wMlg3QDBzIN88US=>NInh[FlUSU6JRWK=
CP66-MELNFS5SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYX2T2JSUUN3ME2wMlg4OTFizszNNVHYdoNLW0GQR1XS
SN12CM3XXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnoTWM2OD1yLki4OlM4KM7:TR?=NUPwZnNTW0GQR1XS
A172MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHS3NmxKSzVyPUCuPFg3QThizszNMmPYV2FPT0WU
NCI-H2347NYTTSllvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvZdmE2UUN3ME2wMlg5PzV|IN88US=>MUTTRW5ITVJ?
NCI-H2228NYLN[m5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrqTnRNUUN3ME2wMlg6OzN7IN88US=>M1G3WXNCVkeHUh?=
SNU-387Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDWcVBKSzVyPUCuPVAzPjRizszNM1;EUHNCVkeHUh?=
SK-MEL-24M3nrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkW0TWM2OD1yLkmxN|Q1KM7:TR?=MYrTRW5ITVJ?
MDA-MB-468MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnZRXh2UUN3ME2wMlkyPzNizszNMl\QV2FPT0WU
NCI-H1694M{Lxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnRe5RKSzVyPUCuPVE5PzZizszNM{fjWXNCVkeHUh?=
CCF-STTG1NUX6TnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTBwOUK2N|ch|ryPNFnFWWNUSU6JRWK=
K052M1Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3:xN2lEPTB;MD65OFA1PyEQvF2=MW\TRW5ITVJ?
NCI-H446MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTBwOUWwNUDPxE1?MUfTRW5ITVJ?
MFE-280MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDGSJRpUUN3ME2wMlk3OjlzIN88US=>M2O0UHNCVkeHUh?=
KU812MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HTemlEPTB;MD65PVM5QSEQvF2=MlHZV2FPT0WU
MDA-MB-361M3y5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTBwOUm3O|ch|ryPMl7NV2FPT0WU
RajiNVm4Sm1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPlOHRQUUN3ME2xMlAzOjZ5IN88US=>MnnnV2FPT0WU
TE-6MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYntXG8xUUN3ME2xMlA{PTZ4IN88US=>M{K5VnNCVkeHUh?=
CAL-148M4LSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXnT2NFUUN3ME2xMlA1PDR|IN88US=>M1fwR3NCVkeHUh?=
NCI-H1963NFrLbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjaW|dKSzVyPUGuNFQ2PTNizszNNIjidJNUSU6JRWK=
SK-N-ASMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPxV|FmUUN3ME2xMlA1Pjh3IN88US=>MkDlV2FPT0WU
RERF-LC-MSMke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7sTWM2OD1zLkC2N|Q6KM7:TR?=MYrTRW5ITVJ?
BENM2nDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzuW4xMUUN3ME2xMlA4OTN5IN88US=>NWr5N5FyW0GQR1XS
CAS-1NF\scHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkj6TWM2OD1zLkC5NVI{KM7:TR?=M{nXW3NCVkeHUh?=
SW780NUfTeGZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTkNW5qUUN3ME2xMlA6OThzIN88US=>Mk\PV2FPT0WU
LU-65MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTFwMEm0NUDPxE1?M2rpT3NCVkeHUh?=
D-283MEDMnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnFV5NRUUN3ME2xMlEzOjd{IN88US=>MWDTRW5ITVJ?
HCC2157MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFm2OYxKSzVyPUGuNVM3PDJizszNMVnTRW5ITVJ?
RCC10RGBMkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\VNmlEPTB;MT6xOFAxPiEQvF2=NFTROZVUSU6JRWK=
PLC-PRF-5NITVdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\NTG5TUUN3ME2xMlE2OjJ7IN88US=>M2GwZ3NCVkeHUh?=
H4MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFwMUW0N|kh|ryPMk\VV2FPT0WU
TURMoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXYTXVKSzVyPUGuNVU4PTJizszNMoi5V2FPT0WU
NCI-H2141M4jv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTFwMUi5OFYh|ryPMln4V2FPT0WU
PFSK-1MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTwSnhKSzVyPUGuNlA2OzJizszNNGLaRmpUSU6JRWK=
SK-MEL-28NFnvbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGK1T5BKSzVyPUGuNlMzOjFizszNM3e1[XNCVkeHUh?=
SCC-9MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHoPHBKSzVyPUGuNlM3PjVizszNNVfkXZUxW0GQR1XS
T47DMnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPxXGxKSzVyPUGuNlM3QTZizszNNF7BSpZUSU6JRWK=
TCCSUPNV3XUWZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\rXpFmUUN3ME2xMlI2ODJ7IN88US=>MV3TRW5ITVJ?
SU-DHL-1MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnTPGxIUUN3ME2xMlI2OTF6IN88US=>NYW1PHA4W0GQR1XS
HL-60MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVL4N4ZqUUN3ME2xMlI2PTh6IN88US=>NEnYe3FUSU6JRWK=
NCI-H1436NFTt[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvmXmFKSzVyPUGuNlYyPDlizszNNXW3UXZJW0GQR1XS
DMS-114M1XUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPufnpKSzVyPUGuNlY3OzJizszNMUPTRW5ITVJ?
BOKUNIDZOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LXTWlEPTB;MT6yPFA6PSEQvF2=NVHqV|hwW0GQR1XS
MS-1M1va[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHu5U4hKSzVyPUGuNlkxPjlizszNMYjTRW5ITVJ?
NCI-H661NVnMcGViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrBfXBKSzVyPUGuN|A1PzhizszNMoPKV2FPT0WU
HT-3Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PjTmlEPTB;MT6zNFUzQSEQvF2=NH;OcmZUSU6JRWK=
CAL-54NXm5[mFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTFwM{C3NlUh|ryPMVjTRW5ITVJ?
SW1463NWjMdVRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTFwM{G4O|Ih|ryPMX;TRW5ITVJ?
COLO-668MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXKzVZR7UUN3ME2xMlM{ODV4IN88US=>NXruVXVYW0GQR1XS
PANC-08-13MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vwd2lEPTB;MT6zN|gxOyEQvF2=M17DOnNCVkeHUh?=
BB49-HNCNWH5cY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTFwM{SwNUDPxE1?Ml\6V2FPT0WU
M059JNWLkT5NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TJTGlEPTB;MT6zOVg{OiEQvF2=NYrJPWs{W0GQR1XS
NCCITM{THbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2r5V2lEPTB;MT6zO|k5QCEQvF2=NIfLSotUSU6JRWK=
LN-405NF\VWnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LRfmlEPTB;MT6zPVI3PCEQvF2=NEfGd2tUSU6JRWK=
UMC-11NETld3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLTS5ZlUUN3ME2xMlM6QTl4IN88US=>NXT6RnppW0GQR1XS
NB5NIj6O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jtfGlEPTB;MT60NVIzPyEQvF2=MYrTRW5ITVJ?
TE-441-TNELOOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTFwNEK4NVch|ryPNGCxdplUSU6JRWK=
ME-180M1voOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjmdYhLUUN3ME2xMlQ1Ozl{IN88US=>MVHTRW5ITVJ?
HCC70NXTFVZJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLPSYtKSzVyPUGuOFYxQTZizszNMUTTRW5ITVJ?
no-10MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYj0R2VpUUN3ME2xMlQ3OThzIN88US=>M{Sx[HNCVkeHUh?=
JEG-3MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHO3OoZKSzVyPUGuOVAyOzJizszNMX7TRW5ITVJ?
no-11M1zrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLzTWM2OD1zLkWwPFgzKM7:TR?=Mn\KV2FPT0WU
CHP-126M2XxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnaV2JKSzVyPUGuOVY3QTFizszNMmPkV2FPT0WU
EGI-1NWfBeGgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEO4fVRKSzVyPUGuOVgxOjVizszNMlzSV2FPT0WU
D-392MGMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\FU2lEPTB;MT61PVY{KM7:TR?=MV3TRW5ITVJ?
RT4NY[0ZZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTlTWM2OD1zLkW5OlM4KM7:TR?=NH3ZWXNUSU6JRWK=
A204M3;xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTFwNUm4NFEh|ryPNYfGXlBmW0GQR1XS
NCI-H1304NUHCXogxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mly0TWM2OD1zLk[zOVkyKM7:TR?=NFPpU3BUSU6JRWK=
BeckerNULqcHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXjUodNUUN3ME2xMlY1OjRzIN88US=>NXzYcXRQW0GQR1XS
OE19MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrtTWM2OD1zLk[1OVE5KM7:TR?=NHvhNXlUSU6JRWK=
EKVXMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHW2T5VKSzVyPUGuOlU3OThizszNNGrhPZFUSU6JRWK=
KLEM3nJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7QTWM2OD1zLk[1O|E1KM7:TR?=MYnTRW5ITVJ?
K-562NHS0WFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mny2TWM2OD1zLk[3NFM4KM7:TR?=M3;0WHNCVkeHUh?=
MDA-MB-175-VIIMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrxTWM2OD1zLk[4PVk4KM7:TR?=MYDTRW5ITVJ?
NCI-H716MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrqOZNKSzVyPUGuOlk{ODRizszNNYL1[pFPW0GQR1XS
Caov-3M4HM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXwdGE5UUN3ME2xMlY6PDF|IN88US=>MVTTRW5ITVJ?
HCC1187NYnB[5JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTFwN{C1OFUh|ryPMYnTRW5ITVJ?
CAKI-1M1fIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDuOWtKSzVyPUGuO|IzQTJizszNNVLvWIVPW0GQR1XS
MOLT-16NHL5UmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPLSVdWUUN3ME2xMlc{OzB5IN88US=>NYW1WYQ{W0GQR1XS
PC-3NUGwTHc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPBbpFKSzVyPUGuO|UxQCEQvF2=MVnTRW5ITVJ?
DV-90NVPlb2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYSzNGJoUUN3ME2xMlc2PTh3IN88US=>NIjTfplUSU6JRWK=
RXF393Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIH3dmJKSzVyPUGuO|czQTRizszNMX\TRW5ITVJ?
SK-NEP-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPjVIlDUUN3ME2xMlgzOzN7IN88US=>MV7TRW5ITVJ?
HCC1419NXPXW2lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjrT29KSzVyPUGuPFI3QTJizszNMoL1V2FPT0WU
BV-173MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojDTWM2OD1zLkiyPVk2KM7:TR?=MWXTRW5ITVJ?
MKN7M2q4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rhTWlEPTB;MT64PVIzKM7:TR?=NUnrXpdmW0GQR1XS
LAN-6MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPwTWM2OD1zLki5OVU{KM7:TR?=MmPkV2FPT0WU
Mo-TNXnIUGhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGWy[3BKSzVyPUGuPVAxOzlizszNM4DSb3NCVkeHUh?=
HCC1395MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTFwOUK4OlMh|ryPNIC3c5NUSU6JRWK=
HC-1Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\UWVlxUUN3ME2xMlk{PDdizszNM2rtdXNCVkeHUh?=
HPAF-IIMmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTFwOUS0NVgh|ryPM3ewUHNCVkeHUh?=
CPC-NNGHJWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\PVlFKSzVyPUGuPVgxODJizszNM120O3NCVkeHUh?=
MKN45NXvFTnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnzRZN3UUN3ME2xMlk6OTF7IN88US=>MojWV2FPT0WU
NCI-H1693MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2L0TWlEPTB;Mj6wNFQ{OyEQvF2=MU\TRW5ITVJ?
SHP-77M4\uUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fG[2lEPTB;Mj6wNFU{OyEQvF2=M{WweHNCVkeHUh?=
NCI-H1522Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NET1d4ZKSzVyPUKuNFE4OjRizszNNILQbHJUSU6JRWK=
SW1573MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXvSlY1UUN3ME2yMlAzOiEQvF2=NVu4PVF[W0GQR1XS
DBTRG-05MGNHf5SpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYqxXmVWUUN3ME2yMlA3ODh5IN88US=>MW\TRW5ITVJ?
SCC-4NUflNWw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1L0bWlEPTB;Mj6xOFMyKM7:TR?=MlPYV2FPT0WU
DMS-153NETZeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTiNlhWUUN3ME2yMlE3PjZ6IN88US=>M{Xtd3NCVkeHUh?=
MDA-MB-415NI\IPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfSb3VKSzVyPUKuNVc2OiEQvF2=M{jQTHNCVkeHUh?=
NCI-H2126NWrBUmFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrETWM2OD1{LkKyPFg5KM7:TR?=MlvNV2FPT0WU
MDA-MB-453NVLLO3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rHNmlEPTB;Mj6yN|MzKM7:TR?=M2mybnNCVkeHUh?=
U-87-MGNX7pTmdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWj6WlFJUUN3ME2yMlI5PTl{IN88US=>MmPEV2FPT0WU
LNCaP-Clone-FGCM37QdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTJwM{CxNFIh|ryPNV3vSJBEW0GQR1XS
NCI-H1581MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvuXGpKSzVyPUKuN|IyODVizszNNVrSdJlOW0GQR1XS
BC-3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVvib5lwUUN3ME2yMlM3PTB7IN88US=>NUH4dYFJW0GQR1XS
HCC38MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPRR3lKSzVyPUKuN|g1PDdizszNM2\VXnNCVkeHUh?=
HCC2218MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TxcmlEPTB;Mj60NFgxQSEQvF2=M2DPWXNCVkeHUh?=
RO82-W-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTJwNEGyOUDPxE1?NXHrcpFOW0GQR1XS
C2BBe1M2LyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfNeJBQUUN3ME2yMlQyPTd6IN88US=>NVz3Xpg5W0GQR1XS
LAMA-84NUmxWnFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TOd2lEPTB;Mj61O|M3QCEQvF2=Mn\yV2FPT0WU
GMS-10M1;tcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\4eXZWUUN3ME2yMlU4PjFzIN88US=>M3nlZXNCVkeHUh?=
GCTMoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3W5N2lEPTB;Mj61PFY6PCEQvF2=MoTZV2FPT0WU
SK-CO-1MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfBb2VEUUN3ME2yMlYyPjZizszNMX7TRW5ITVJ?
NCI-H526NU\iOpFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjXOlJKSzVyPUKuOlM1PSEQvF2=NGXFSpdUSU6JRWK=
SW1088MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjVTWM2OD1{Lke3PFM6KM7:TR?=M1PkTHNCVkeHUh?=
HT55NHLIcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrzWINKSzVyPUKuO|g3QTVizszNM2TieHNCVkeHUh?=
NB10NGLQe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjI[2xlUUN3ME2yMlgyPzR6IN88US=>MlPUV2FPT0WU
UACC-893MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnv0TWM2OD1{Lki1O|Q6KM7:TR?=M3TEZnNCVkeHUh?=
NCI-H1618MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\kVGlEPTB;Mj64PFE2OyEQvF2=NUm1S3NDW0GQR1XS
NCI-H1092MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXtTWM2OD1|LkC3PFEzKM7:TR?=MmP0V2FPT0WU
SBC-1M{\3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH20VZVKSzVyPUOuNFg2PTNizszNM4rCN3NCVkeHUh?=
NCI-H1623M{TQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjifHJKSzVyPUOuNFk{PCEQvF2=MkmyV2FPT0WU
SiHaNVHoXHU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fLWGlEPTB;Mz6xNVk4PyEQvF2=NETZeopUSU6JRWK=
D-263MGMn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17MTWlEPTB;Mz6xOFc5QCEQvF2=MXLTRW5ITVJ?
NCI-H1573MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ThWWlEPTB;Mz6xPVY1OSEQvF2=Mo\xV2FPT0WU
NCI-H82MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPmVGhWUUN3ME2zMlM1PDN7IN88US=>MmG5V2FPT0WU
NCI-H2196NXvmZYNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nZb2lEPTB;Mz6zOVAxQCEQvF2=MXnTRW5ITVJ?
MFM-223M3rpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\kdJpKSzVyPUOuN|c{PTFizszNM1SxbXNCVkeHUh?=
COLO-678MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTNwM{ixPFYh|ryPMkjrV2FPT0WU
EW-3M{PBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjoTWM2OD1|LkSwPVUh|ryPNV3mRoc4W0GQR1XS
MHH-NB-11NIexTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDETllKSzVyPUOuOFQxPjlizszNMVvTRW5ITVJ?
EM-2MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13FR2lEPTB;Mz62N|k5KM7:TR?=NX;VfFhEW0GQR1XS
FTC-133MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fNOWlEPTB;Mz62OVQ2QCEQvF2=NWrlWXNTW0GQR1XS
NCI-H209NW\XZ3FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTNwNke2OVMh|ryPM2SwTXNCVkeHUh?=
TGBC24TKBMmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3f0bWlEPTB;Mz62PFM2PSEQvF2=MYjTRW5ITVJ?
LC-1FNHyySnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTNwN{G3OlQh|ryPNVHIdW5xW0GQR1XS
C-4-IINUTFOlhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\1TWM2OD1|Lke1OlQ{KM7:TR?=M1zLNHNCVkeHUh?=
NCI-H1650MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTNwN{i0OVUh|ryPNHrhXVhUSU6JRWK=
JVM-2Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGqyTGRKSzVyPUOuPVM3OzlizszNMX;TRW5ITVJ?
CaR-1NIfZS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvH[IViUUN3ME2zMlk4PjF5IN88US=>NFy4V5lUSU6JRWK=
MDA-MB-134-VIMoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDzXI9EUUN3ME20MlAzQTV{IN88US=>M2\mNXNCVkeHUh?=
NCI-H719NIrENHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\2RXBKSzVyPUSuNVU{QDhizszNNYLlV4l{W0GQR1XS
GOTONV;DfXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnf0TWM2OD12LkK5O|A2KM7:TR?=MWjTRW5ITVJ?
NCI-N87NULGZ4lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfWclgzUUN3ME20MlM5QDJzIN88US=>MXnTRW5ITVJ?
NB6M4KzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXHTWM2OD12LkSyOVA6KM7:TR?=MlzKV2FPT0WU
DSH1NEfnTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\INmlEPTB;ND60O|EyPiEQvF2=Mn\QV2FPT0WU
BT-20NYXyNXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnuzTWM2OD12LkS5NFAzKM7:TR?=NIrQbYFUSU6JRWK=
NCI-H1882M4r4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnqTllUUUN3ME20MlUxPTdizszNNULSZlZ4W0GQR1XS
WM-115NGPSWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLvb3pYUUN3ME20MlUxQDhzIN88US=>NFLUdlRUSU6JRWK=
SKG-IIIaMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnmVoJKSzVyPUSuOlc4PyEQvF2=M1L3NnNCVkeHUh?=
NCI-H69MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvXTWM2OD12LkewNlc2KM7:TR?=NG\xRXJUSU6JRWK=
MSTO-211HMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13OfWlEPTB;ND64N|U3PSEQvF2=MnzIV2FPT0WU
MewoM2DvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfCTWM2OD12Lkm2N|E{KM7:TR?=NFviNXZUSU6JRWK=
GI-ME-NM1jUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELtXFlKSzVyPUWuNFA2ODlizszNMlO4V2FPT0WU
T98GM3Lxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XDNWlEPTB;NT6wOlUxQCEQvF2=Mn21V2FPT0WU
ECC4MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFf4cY1KSzVyPUWuNFk{PzJizszNMmP2V2FPT0WU
EW-11NVK0W2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXLVYs5UUN3ME21MlE5ODl7IN88US=>NYDmW|ZvW0GQR1XS
COLO-800NYSwbplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17HfGlEPTB;NT6xPVM1QSEQvF2=NYLpN5NWW0GQR1XS
NCI-H1755NUjHN21IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPGXXpKUUN3ME21MlI{ODJ5IN88US=>NF;CZlNUSU6JRWK=
KMS-12-PENIrVUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTVwM{WwPFUh|ryPM1m4N3NCVkeHUh?=
HCC1954NV7scnA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTVwOEW5O|Eh|ryPM4TIZXNCVkeHUh?=
NCI-H187Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVr6Z5Y3UUN3ME21MlkzQTh7IN88US=>MmDZV2FPT0WU
LU-165NYLhXJdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzRUGhKSzVyPUWuPVkxODJizszNNGDHXJZUSU6JRWK=
YAPCNGTuV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{L5NmlEPTB;NT65PVA3QCEQvF2=MWPTRW5ITVJ?
LU-139NVT5cZlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7ZVHRKSzVyPU[uNFg{PjhizszNNGnU[XRUSU6JRWK=
D-502MGNUDEbZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPmTWxKSzVyPU[uN|IxPDdizszNNUTkOGRTW0GQR1XS
IST-SL1NYrMfYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH61cIZKSzVyPU[uOVM6PDhizszNM1nHVXNCVkeHUh?=
DG-75MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{H3R2lEPTB;Nj64PFc5PiEQvF2=MnfIV2FPT0WU
NCI-H1155MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTZwOUW1PFEh|ryPMlHPV2FPT0WU
EFE-184MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rZb2lEPTB;Nz6zNVY6PSEQvF2=NIfxOWFUSU6JRWK=
AsPC-1MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLaWIhKSzVyPUeuOFg5ODdizszNMYXTRW5ITVJ?
SW948NEDXVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTdwNUizPVUh|ryPMYLTRW5ITVJ?
NCI-H524Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTlwNUi2Nlgh|ryPMWLTRW5ITVJ?
KOSC-2NELrUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jEeWlEPTB;OT62Nlg{PCEQvF2=M3nORXNCVkeHUh?=
T-24NGq5d45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHOU3pKSzVyPUmuPVQ1OTVizszNMmDyV2FPT0WU
NCI-H748NUC4fJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTFyLk[zPVch|ryPMV\TRW5ITVJ?
NCI-H23NHG1[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTFyLk[0OFIh|ryPMVnTRW5ITVJ?
UACC-812MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XSZ2lEPTB;MUGuO|E4KM7:TR?=NHPUdIpUSU6JRWK=
SCLC-21HNEDm[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTF{LkG1OVEh|ryPM4nlbHNCVkeHUh?=
NCI-SNU-16NXeydHI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHucldKSzVyPUGzMlEzPThizszNM{KzRnNCVkeHUh?=
HD-MY-ZM176RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrFVZpUUUN3ME2xOE43OzZ|IN88US=>M3W4WnNCVkeHUh?=
SK-N-FINULvephwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTF2Lki5NVIh|ryPMY\TRW5ITVJ?
LB647-SCLCNGnRXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTkTWM2OD1zNT63NVk2KM7:TR?=MVTTRW5ITVJ?
NCI-H345M2jwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlH2TWM2OD1zNz6zOFMh|ryPNGnJOIFUSU6JRWK=
NCI-H1563NGH4S29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzOT3VKSzVyPUG4Mlc3ODFizszNMmfvV2FPT0WU
RLM3\COGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4i1R2lEPTB;MkGuNlY2PiEQvF2=NHPTPHNUSU6JRWK=
KY821MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TQ[2lEPTB;MkKuNFU2OyEQvF2=MnHlV2FPT0WU
JVM-3NFHrSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LWZWlEPTB;MkWuNFQyOyEQvF2=M4jpPHNCVkeHUh?=
NCI-H1793M1LhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrIWZdKSzVyPUK4MlU1QTlizszNMmfBV2FPT0WU
LU-134-AMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTNyLkKwN|ch|ryPM4fGdnNCVkeHUh?=
NCI-H1395M1nEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTvTWM2OD1|Mj6yOFMyKM7:TR?=NVnnfJFLW0GQR1XS
NCI-H1993MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTN{LkiyNVgh|ryPNHPmPGlUSU6JRWK=
P31-FUJM4DGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETkV3RKSzVyPUOzMlQ5QTlizszNNIrnPXlUSU6JRWK=
LS-513MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vVWWlEPTB;M{WuPFg4QSEQvF2=MoX3V2FPT0WU
SK-MEL-1NFfYWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnITWM2OD12MD6zOFk6KM7:TR?=MkjSV2FPT0WU
SW684Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLuV4J[UUN3ME20N{46PjZzIN88US=>MWrTRW5ITVJ?
COR-L88M1PkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLETWM2OD12ND6wOlY2KM7:TR?=M{TPbnNCVkeHUh?=
NCI-H889NVHneFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTR3LkCwPFch|ryPMXfTRW5ITVJ?
TALL-1MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTR4LkGxPVkh|ryPNH;hZ5FUSU6JRWK=
KARPAS-299MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnLTWM2OD12Nz6xPVk{KM7:TR?=NXTZNoNKW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Protocol(Only for Reference)

Kinase Assay: [1]

Bcl-2 Binding affinity calculation A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.

Cell Assay: [2]

Cell lines Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
Concentrations ~10 μM
Incubation Time 48-72 hours
Method Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.

Animal Study: [1]

Animal Models Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
Formulation Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
Dosages 0.0313, 0.25, 0.5 and 2 mg/kg
Administration Administered intravenously (tail vein) once a day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Nguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517.

[2] Trudel S, et al. Blood, 2009, 113(2), 299-305.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymp  ...more Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|  ...more Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2

view more

Chemical Information

Download Obatoclax Mesylate (GX15-070) SDF
Molecular Weight (MW) 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 83 mg/mL (200.73 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (Z)-2-(5-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-4-methoxy-5H-pyrrol-2-yl)-1H-indole mesylate

Customer Product Validation (9)


Click to enlarge
Rating
Source Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunohistochemical staining
Cell Lines Mice
Concentrations 3 mg/kg
Incubation Time 3 weeks
Results Tumors from 3 mice in each group were analyzed with H&E and immunohistochemical staining. Interestingly, H&E staining revealed substantially increased necrosis in the tumors for GX15-070 treated groups compared to the vehicle control group, especially for the combination (AZD2281 and GX15-070) group.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Electron microscopic morphology
Cell Lines T1682 cells
Concentrations 100, 1000 nM
Incubation Time 1, 6, 48 h
Results Gx15-070 treatment of TET cells leads to both growth inhibition and cell death. Gx15-070 induces autophagy-dependent necroptosis in acute lymphoblastic leukemia cells, it's performed electron microscopy (EM) in TET cells, which demonstrated changes in mitochondrial structure as early signs of autophagy after 1 h Gx15-070 treatment. After 6 h treatment, cytoplasmic vacuolization and mitochondrial swelling with early signs of necroptotic cell death were evident. Intriguingly, cytoplasmic vacuolization, late-stage necroptotic or autophagic cell death were the main features 48 h after Gx15-070 (1 uM) treatment.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Western blot
Cell Lines T1682 cells
Concentrations 100, 250, 500, 1000 nM
Incubation Time 6 h
Results Gx15-070 induced a progressive reduction of AKT Ser473 and Thr308 phosphorylation and a reduction of p-RPS6 phosphorylation, suggesting inhibition of mTOR pathway, in line with previous reports. Moreover, Gx15-070 induced phosphorylation of AMPKα, a Ser/Thr kinase normally activated when ATP level is reduced.AMPK phosphorylation and LC3B cleavage appeared within 1 h after Gx15-070 treatment.

Click to enlarge
Rating
Source Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Viability assay
Cell Lines BM3.3 CD8 T cells
Concentrations 0.1-10uM
Incubation Time
Results T-cell activation induced resistance to Bcl-2 inhibition by ABT-737 (no binding of A1 and Mcl-1) and by Antimycin A (no binding of A1 only), but had no impact on the proapoptotic potency of the pan-Bcl-2 inhibitor obatoclax.

Click to enlarge
Rating
Source Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunostaining
Cell Lines HUH6 cells
Concentrations 0.1, 0.3 uM
Incubation Time 24 h
Results In HUH6 cells mitochondria with an intact membrane potential were observed in the JC-1 staining in both, control and TNF-a treated cultures (C, D). The number of reddish points indicating active mitochondria decreased when the HUH6 cells were treated with obatoclax and decreased even further when the treatment was performed in combination with TNF-a, which reflects the breakdown of mitochondrial membranes decreased aggregation of JC-1. This was concentration dependent (E-H).

Click to enlarge
Rating
Source BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell proliferation assays
Cell Lines SET-2 cells
Concentrations 1-10000 nM
Incubation Time 72 h
Results Incubation of SET-2 cells with sub-optimal concentrations of the pan-Bcl-2 family protein inhibitor obatoclax in cell proliferation assays lowered the GI 50 of NVP-BSK805 by 3 to 4 fold.

Click to enlarge
Rating
Source Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Clonogenic survival assay
Cell Lines MEF cells
Concentrations 0-300 ng/mL
Incubation Time 24 h
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Hoechst staining
Cell Lines MDB-MA-231 cells
Concentrations 1 μM
Incubation Time
Results

Click to enlarge
Rating
Source Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell Viability/Western Blot
Cell Lines Nalm-6 ABT-R cells
Concentrations 5-10 uM
Incubation Time 18 h
Results Nalm-6 ABT-R cells were sensitive to obatoclax; however, Nalm-6 cells were equally sensitive (IC50: 10 umol/L). Reh parental cells (IC50: 5umol/L) were also more sensitive to obatoclax compared with ABT-R cells, as measured by trypan blue exclusion. Mcl-1 protein levels were downregulated following obatoclax treatment. NOXA levels also increased, however these changes did not correlate with cell death.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcl-2 Products

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Recently Viewed Items

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us